horizon for patients with metastatic PDAC significantly changed with the multiagent chemotherapy regimens fluorouracil/folinic acid/irinotecan/oxaliplatin (FOLFIRINOX) 4 and gemcitabine/nab-paclitaxel, 5 respectively. Median survival for patients with
Search Results
Zhi Ven Fong and Cristina R. Ferrone
A. Dimitrios Colevas
SCCHN. 9 - 15 The most robustly studied agents are cisplatin, carboplatin, methotrexate, 5-fluorouracil (5-FU), ifosfamide, paclitaxel, and docetaxel ( Table 1 ). Response rates typically range from 10% to 30%, with some outlier reports of higher
Michael Xiang, A. Dimitrios Colevas, F. Christopher Holsinger, Quynh-Thu X. Le, and Beth M. Beadle
combination chemotherapy ( Figure 2A ), which was predominantly with paclitaxel. By contrast, 86% of patients in the cisplatin cohort received cisplatin monotherapy ( Figure 2B ). H&N CSM was higher for single-agent carboplatin than for multiagent chemotherapy
Aatur D. Singhi, Siraj M. Ali, Jill Lacy, Andrew Hendifar, Khanh Nguyen, Jamie Koo, Jon H. Chung, Joel Greenbowe, Jeffrey S. Ross, Marina N. Nikiforova, Herbert J. Zeh, Inderpal S. Sarkaria, Anil Dasyam, and Nathan Bahary
regimens, including gemcitabine plus nab-paclitaxel and FOLFIRINOX (5-fluorouracil, folinic acid, oxaliplatin, and irinotecan), have limited efficacy, with an incremental survival benefit of only a few months in unselected patients. However, significant
Héctor G. van den Boorn, Willemieke P.M. Dijksterhuis, Lydia G.M. van der Geest, Judith de Vos-Geelen, Marc G. Besselink, Johanna W. Wilmink, Martijn G.H. van Oijen, and Hanneke W.M. van Laarhoven
: Fluoropyrimidine, platinum, and irinotecan (eg, FOLFIRINOX [5-FU/leucovorin/oxaliplatin/irinotecan]) Regimens with gemcitabine and nab-paclitaxel Gemcitabine monotherapy Other regimens Predictor Preselection Predictors were selected based on
Medhavi Gupta, Christopher Sherrow, Maghan E. Krone, Edik M. Blais, Michael J. Pishvaian, Emanuel F. Petricoin III, Lynn M. Matrisian, Patricia DeArbeloa, Gary Gregory, Alyson Brown, Olivia Zalewski, Gillian Prinzing, Charles Roche, Kazunori Kanehira, Sarbajit Mukherjee, Renuka Iyer, and Christos Fountzilas
surveillance CT 6 months later showed disease progression with enlarging lymph nodes. Gemcitabine was reintroduced at a lower dose of 800 mg/m 2 on days 1 and 8 of a 21-day cycle. Nab-paclitaxel was added to gemcitabine from cycle 6 onward because of further
Jing Xi, Aabha Oza, Shana Thomas, Foluso Ademuyiwa, Katherine Weilbaecher, Rama Suresh, Ron Bose, Mathew Cherian, Leonel Hernandez-Aya, Ashley Frith, Lindsay Peterson, Jingqin Luo, Jairam Krishnamurthy, and Cynthia X. Ma
+ everolimus (n=12), exemestane + entinostat (n=2), or fulvestrant + palbociclib (n=2). The most common regimens after progression on palbociclib were single-agent capecitabine (n=21), eribulin (n=16), nab-paclitaxel (n=15), and exemestane + everolimus (n=12
Eva Battaglini, David Goldstein, Peter Grimison, Susan McCullough, Phil Mendoza-Jones, and Susanna B. Park
treatments for these cancers: taxanes (docetaxel: n=322 [32.7%]; paclitaxel: n=312 [31.6%]), platinum-based chemotherapies (oxaliplatin: n=123 [12.5%]; cisplatin: n=53 [5.4%]), thalidomide (n=87; 8.8%), and bortezomib (n=82; 8.3%). One-quarter of respondents
Robert W. Carlson, Susan J. Moench, M. Elizabeth H. Hammond, Edith A. Perez, Harold J. Burstein, D. Craig Allred, Charles L. Vogel, Lori J. Goldstein, George Somlo, William J. Gradishar, Clifford A. Hudis, Mohammad Jahanzeb, Azadeh Stark, Antonio C. Wolff, Michael F. Press, Eric P. Winer, Soonmyung Paik, Britt-Marie Ljung, and for the NCCN HER2 Testing in Breast Cancer Task Force
cyclophosphamide followed by paclitaxel. 35 These results support the hypothesis that the pro-proliferative/pro-angiogenic/pro-apoptotic/ invasive signals characteristic of dysregulated c-myc genes 42 acting in concert with the anti-apoptotic signals associated
Ashley Tabah, David Huggar, Ronda Copher, Marc Tian, and Ali McBride
analysis included adult patients diagnosed with mNSCLC who initiated nab-paclitaxel, sb-paclitaxel, or PD-L1 based 1L therapy from 1/1/2011 to 12/31/2017. Patients were continuously enrolled (CE) with medical and pharmacy benefits ≥6 months prior to mNSCLC
